How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver

Summary

Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.

Conditions

• Metabolic Dysfunction-Associated Steatotic Liver Disease
• Non-Alcoholic Steato-Hepatitis (NASH)
• Type 1 Diabetes Mellitus

Interventions

DIAGNOSTIC_TEST

Imaging PET/MRI

MRI using 1H-MRS and Dixon sequences on a 3 T clinical MRI system (Ingenia, Philips Healthcare, Best, the Netherlands) will be performed. \[11C\]-palmitate: 1 x i.v. injection of 175 MBq followed by TEP imaging. \[18F\]-FTHA: oral administration of 75 MBq followed by TEP imaging.

DIAGNOSTIC_TEST

Stable isotope infusions

\[6,6 D2\]-glucose infusion (0.22 µmol/kg/min, preceded by a bolus of 22 µmol/kg) will start from -180 until time + 360. \[1,1,2,3,3-2H\]-glycerol (0.05 µmol/kg/min.) and of \[7,7,8,8-2H\] palmitate (0.01 µmol/kg/min) will start from time -60 until time +360.

DIAGNOSTIC_TEST

meal test

A liquid meal will be administered at time 0. The liquid meal (400 ml) energy breakdown is 50% (101g) from glucose, 33% (31g) from fat, and 17% (40g) from protein; participants will consume the 400 ml in 4 aliquots of 100 ml over 20 min, supplemented with 0.9 g of U-\[13C\]-glucose and 9 μmol/kg lean mass of \[U-13C\]-palmitate.

DIAGNOSTIC_TEST

Indirect calorimetry

Indirect calorimetry (Vmax Series from Vyaire medical, licence # 22536), measured during10 minutes, every hour.

Sponsors & Collaborators

• Centre de recherche du Centre hospitalier universitaire de Sherbrooke

  collaborator OTHER

• Université de Sherbrooke

  lead OTHER

Principal Investigators

• André C Carpentier, MD · Université de Sherbrooke

Study Design

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

21 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2026-09-30

Primary Completion

2027-09-30

Completion

2028-12-31

Countries

• Canada

Study Locations